Neuberger Berman Group
FATE icon

Neuberger Berman Group’s Fate Therapeutics FATE Stock Holding History

Neuberger Berman Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.1K Buy
16,696
+1,346
+9% +$2.49K ﹤0.01% 2291
2026
Q1 		$18.4K Buy
15,350
+1,400
+10% +$1.71K ﹤0.01% 2149
2025
Q4 		$13.7K Buy
+13,950
New +$16.8K ﹤0.01% 2101
2024
Q1 		– Sell
-21,274
Closed -$79.6K – 1864
2023
Q4 		$79.6K Buy
+21,274
New +$50.2K ﹤0.01% 1817
2022
Q4 		– Sell
-376,683
Closed -$8.44M – 1818
2022
Q3 		$8.44M Sell
376,683
-266
-0.1% -$7.69K 0.01% 776
2022
Q2 		$9.34M Buy
376,949
+18,757
+5% +$518K 0.01% 763
2022
Q1 		$13.9M Buy
358,192
+5,856
+2% +$227K 0.01% 746
2021
Q4 		$20.6M Sell
352,336
-32,851
-9% -$1.86M 0.02% 683
2021
Q3 		$22.7M Buy
385,187
+124,894
+48% +$9.8M 0.02% 643
2021
Q2 		$22.6M Buy
260,293
+203,610
+359% +$16.4M 0.02% 672
2021
Q1 		$4.64M Sell
56,683
-4,317
-7% -$414K ﹤0.01% 969
2020
Q4 		$5.55M Hold
61,000
– – 0.01% 888
2020
Q3 		$2.44M Buy
61,000
+24,000
+65% +$838K ﹤0.01% 1029
2020
Q2 		$1.27M Hold
37,000
– – ﹤0.01% 1091
2020
Q1 		$822K Sell
37,000
-53,000
-59% -$1.34M ﹤0.01% 1135
2019
Q4 		$1.76M Sell
90,000
-17,400
-16% -$276K ﹤0.01% 1057
2019
Q3 		$1.67M Buy
107,400
+11,400
+12% +$219K ﹤0.01% 1051
2019
Q2 		$1.95M Buy
96,000
+36,000
+60% +$649K ﹤0.01% 1040
2019
Q1 		$1.05M Hold
60,000
– – ﹤0.01% 1108
2018
Q4 		$770K Sell
60,000
-60,000
-50% -$837K ﹤0.01% 1167
2018
Q3 		$1.96M Buy
120,000
+105,000
+700% +$1.24M ﹤0.01% 1037
2018
Q2 		$170K Sell
15,000
-138,250
-90% -$1.52M ﹤0.01% 1662
2018
Q1 		$1.5M Sell
153,250
-20,000
-12% -$192K ﹤0.01% 1077
2017
Q4 		$1.06M Buy
173,250
+40,250
+30% +$180K ﹤0.01% 1185
2017
Q3 		$527K Buy
133,000
+83,300
+168% +$283K ﹤0.01% 1293
2017
Q2 		$161K Sell
49,700
-18,900
-28% -$72.4K ﹤0.01% 1549
2017
Q1 		$312K Buy
+68,600
New +$251K ﹤0.01% 1412

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Neuberger Berman Group's FATE Position: Q2 2026 in Review

Neuberger Berman Group increased its Fate Therapeutics (FATE) stake by 8.8% in Q2 2026, buying an estimated $2.49K and bringing the position to 16,696 shares worth $45.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2291.

Neuberger Berman Group first reported a position in FATE in Q1 2017 and has held it in 27 quarters since. The position peaked at $22.7M in Q3 2021. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Neuberger Berman Group held 16,696 shares of Fate Therapeutics worth $45.1K as of Q2 2026.
  • Neuberger Berman Group bought 1,346 Fate Therapeutics shares in Q2 2026, an estimated $2.49K.
  • Fate Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2291 holding.
  • Neuberger Berman Group first reported a position in Fate Therapeutics in Q1 2017 and has held it in 27 quarters since.
  • Neuberger Berman Group's Fate Therapeutics position peaked at $22.7M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.